The modern treatment of heart failure is characterized by early intervention, multidimensional care and extended therapy options. Around half of all heart failure patients have a reduced left ventricular ejection fraction. With regard to drug therapy, according to ESC guidelines, there are four standard recommended drug classes that should be used early in HFrEF, as they are particularly important for reducing morbidity and mortality. SGLT-2 inhibitors are now recommended for HFrEF, HFmrEF and HFpEF.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- From symptom to diagnosis
Multilocular cystic renal cell carcinoma (MCRCC)
- Shaping the Future with LLM & Co.
AI in Everyday Clinical Practice: Friend or Foe?
- Ulcerative colitis: current evidence on anti-inflammatory therapies
Remission induction and maintenance with biologics and JAK-i
- Bronchiectasis
New strategies against neutrophilic inflammation
- IBD in childhood
Pneumococcal vaccination without negative consequences
- Seborrheic Dermatitis in Adults and Adolescents
Current State of Knowledge and New Therapeutic Approaches
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Orthobiologics for knee osteoarthritis